These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 18612199)

  • 21. [Diminished glomerular filtration rate as a marker of chronic kidney disease in hypertensive patients].
    Grabysa R; Cholewa M
    Pol Merkur Lekarski; 2008 Jun; 24(144):487-91. PubMed ID: 18702327
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lipid abnormalities associated with end-stage renal disease.
    Liu J; Rosner MH
    Semin Dial; 2006; 19(1):32-40. PubMed ID: 16423180
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lipid management in chronic kidney disease, hemodialysis, and transplantation.
    Montague T; Murphy B
    Endocrinol Metab Clin North Am; 2009 Mar; 38(1):223-34. PubMed ID: 19217521
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapeutic tools for dyslipidemia in peritoneal dialysis patients.
    Scarpioni R
    J Nephrol; 2009; 22(1):46-58. PubMed ID: 19229818
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcomes of stage 3-5 chronic kidney disease before end-stage renal disease at a single center in Taiwan.
    Chiu YL; Chien KL; Lin SL; Chen YM; Tsai TJ; Wu KD
    Nephron Clin Pract; 2008; 109(3):c109-18. PubMed ID: 18663322
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alterations of lipid metabolism in chronic nephropathies: mechanisms, diagnosis and treatment.
    Lacquaniti A; Bolignano D; Donato V; Bono C; Fazio MR; Buemi M
    Kidney Blood Press Res; 2010; 33(2):100-10. PubMed ID: 20357496
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dyslipidemia in chronic kidney disease: managing a high-risk combination.
    Chauhan V; Vaid M
    Postgrad Med; 2009 Nov; 121(6):54-61. PubMed ID: 19940417
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Endothelial dysfunction and chronic kidney disease: treatment options.
    Wu-Wong JR
    Curr Opin Investig Drugs; 2008 Sep; 9(9):970-82. PubMed ID: 18729004
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Statins and kidney disease].
    Bigazzi R; Grimaldi D; Bianchi S
    G Ital Nefrol; 2012; 29(2):160-73. PubMed ID: 22538946
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Angiopoietin 2 and cardiovascular disease in dialysis and kidney transplantation.
    David S; Kümpers P; Hellpap J; Horn R; Leitolf H; Haller H; Kielstein JT
    Am J Kidney Dis; 2009 May; 53(5):770-8. PubMed ID: 19268412
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dyslipidemia in dialysis patients.
    Mitwalli AH; Alam AA; Al Wakeel JS; Isnani AC
    Saudi J Kidney Dis Transpl; 2011 Jul; 22(4):689-94. PubMed ID: 21743212
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reasons for the lack of salutary effects of cholesterol-lowering interventions in end-stage renal disease populations.
    Vaziri ND; Norris KC
    Blood Purif; 2013; 35(1-3):31-6. PubMed ID: 23343544
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dyslipidemia, statins, and CKD patients' outcomes - review of the evidence in the post-sharp era.
    Heymann EP; Kassimatis TI; Goldsmith DJ
    J Nephrol; 2012; 25(4):460-72. PubMed ID: 22641572
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chronic kidney disease and cardiovascular disease: a case presentation.
    McCarley PB; Salai PB
    Nephrol Nurs J; 2007; 34(2):187-98; quiz 199-200. PubMed ID: 17486949
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Is lipid management effective for all stages of CKD?
    Ku E; Campese V
    Blood Purif; 2013; 35(1-3):26-30. PubMed ID: 23343543
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The renal patient with cardiovascular disease--no longer a simple plumbing problem.
    Tunuguntla A; Yerra L
    Tenn Med; 2005 Aug; 98(8):395-6, 399. PubMed ID: 16315466
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The natural history of chronic kidney disease revisited--a 72-month Mayo Health System Hypertension Clinic practice-based research network prospective report on end-stage renal disease and death rates in 100 high-risk chronic kidney disease patients: a call for circumspection.
    Onuigbo MA
    Adv Perit Dial; 2009; 25():85-8. PubMed ID: 19886324
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PCSK9 in chronic kidney disease.
    Pavlakou P; Liberopoulos E; Dounousi E; Elisaf M
    Int Urol Nephrol; 2017 Jun; 49(6):1015-1024. PubMed ID: 28084558
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dyslipidaemia and cardiorenal disease: mechanisms, therapeutic opportunities and clinical trials.
    Chan DT; Irish AB; Dogra GK; Watts GF
    Atherosclerosis; 2008 Feb; 196(2):823-34. PubMed ID: 17343861
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Cardiorenal syndrome].
    Portolés Pérez J; Cuevas Bou X
    Nefrologia; 2008; 28 Suppl 3():29-32. PubMed ID: 19018735
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.